HIV/AIDS
Jennifer Cocohoba, Pharm.D., BCPS, AAHIVE
Associate Clinical Professor of Health Sciences, School of Pharmacy
Clinical Pharmacist, UCSF Womens HIV Program
University of California, San Francisco
Dr. Cocohoba serves as the clinical pharmacist for the UCSF Women’s HIV Program where she runs an antiretroviral treatment adherence program and provides consultations for patients and providers regarding antiretroviral therapy, drug interactions, and resistance testing. She has served as faculty for various programs of the San Francisco AIDS Education and Training Centers, and educates student pharmacists, pharmacy residents, and nursing students on the topics of adherence, communication, and HIV pharmacotherapy. Dr. Cocohoba was granted a K23 career development award from the National Institutes of Mental Health to study pharmacy interventions to increase adherence to HIV therapy. She serves on the boards of the Northern California College of Clinical Pharmacy and the Golden Gate Chapter of the California Society of Health Systems Pharmacists.
Presented on: Monday, March 12, 2012
Duration: Content: ~48 minutes
Presentation Outline
-Pharmacogenomic effects of HIV/AIDS medications
- Abacavir
–Major histocompatibility complex, Class I (HLA-B*5701)
- Nevirapine
–Major histocompatibility complex, Class I (HLA-B*5701)
–Major histocompatibility complex, Class II (HLA-DRB1)
–ABC transporter gene (ABCB1)
- Efavirenz
–Cytochrome P450 (CYP) 2B6
- Atazanavir
–Uridine diphosphate-glucuronosyltransferase
Learning Objectives
-Upon completion of this program, participants will be able to:
- Identify specifc drug therapies used in asthma for which pharmacogenomic testing can be applied in the clinical setting
- Summarize evidence-based recommendations for pharmacogenomic testing
- Using patient case scenarios, formulate a plan for pharmacogenomics testing based upon available scientific evidence
HIV/AIDSTo access the presentation, please register, login, and click "view" below. view |